

## EdiGene raises \$10M in Series pre-B

06 February 2019 | News

The new round of financing is led by new investor Green Pine Capital Partners.



EdiGene Inc., headquartered in Beijing, with operational subsidiaries in Guangzhou, China and Cambridge, USA and which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery, has announced the successful completion of approximately \$10 Million in a Series pre-B Plus financing, and strengthening of its management team by naming Yun Li, MD, as Vice President of Clinical Development.

The new round of financing is led by new investor Green Pine Capital Partners (Green Pine). Series A lead investor IDG Capital, Series B lead investor Lilly Asia Ventures (LAV) and other insiders also participated in this round.

Yun Li, MD, has joined EdiGene as Vice President of Clinical Development. Dr. Li has more than 20 years of experience in clinical trials of novel therapeutics, mainly focusing on oncology & hematology and immunological phase I-III clinical trials.